Algorithms for prescribing menopausal hormone therapy in different periods of menopause

Authors

  • T.F. Tatarchuk SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”; State Scientific Institution “Center for Innovative Medical Technologies of the NAS of Ukraine”, Kyiv, Ukraine https://orcid.org/0000-0002-5498-4143
  • N.F. Zakharenko SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”; Institute for Planning Family Clinic, Kyiv, Ukraine https://orcid.org/0000-0003-2934-3157
  • S.I. Reheda SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”; SSI “Center for Innovative Medical Technologies of the NAS of Ukraine”, Kyiv, Ukraine https://orcid.org/0000-0002-4960-7175
  • T.I. Kvasha SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”, Kyiv, Ukraine https://orcid.org/0000-0001-7936-2538

DOI:

https://doi.org/10.18370/2309-4117.2022.66.68-70

Keywords:

menopausal hormone therapy, menopause, genitourinary syndrome of menopause, treatment of estrogens deficiency, individualization of therapy

Abstract

Menopausal hormone therapy (MHT) remains the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause. MHT, initiated in women during the “therapeutic window” to relieve symptoms of estrogens deficiency and prevent or treat osteoporosis, is the only intervention that reduces the risk of cardiovascular diseases and diabetes in healthy middle-aged women. MHT must be individualized and adapted; that is, a differentiated selection of therapy should be carried out, considering the woman’s health status and her comorbidities, as well as the MHT regimen (type, dose, route of administration and possible side effects). The article reflects the algorithms for prescribing MHT in different periods of menopause, which allow applying an individualized approach to patients who need MHT.

Author Biographies

T.F. Tatarchuk, SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”; State Scientific Institution “Center for Innovative Medical Technologies of the NAS of Ukraine”, Kyiv

MD, professor, corresponding member of the NAMS of Ukraine, deputy director for research work, head of the Endocrine Gynecology Department;
Chief researcher, Department of Reproductive Health

N.F. Zakharenko, SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”; Institute for Planning Family Clinic, Kyiv

MD, leading research fellow, Endocrine Gynecology Department;
Chairman of the Academic Counci

S.I. Reheda, SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”; SSI “Center for Innovative Medical Technologies of the NAS of Ukraine”, Kyiv

PhD, senior researcher, Endocrine Gynecology Department;
Head of the Gynecology Department

T.I. Kvasha, SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”, Kyiv

PhD, senior researcher, Endocrine Gynecology Department

References

  1. Уніфікований клінічний протокол первинної, вторинної (спеціалізованої), третинної (високоспеціалізованої) медичної допомоги «Менопаузальні порушення та інші розлади в перименопаузальному періоді». Available from: [https://www.dec.gov.ua/mtd/ menopauzalni-porushennya-ta-inshi-rozlady-v-perymenopauzalnomu-periodi/].
  2. Nappi, R.E., Simoncini, T. “Menopausal transition: a golden age to prevent cardiovascular disease.” Lancet Diabetes Endocrinol 9.3 (2021): 135–7. DOI: 10.1016/S2213-8587(21)00018. Available from: [https://www.thelancet.com/journals/landia/article/ PIIS2213-8587(21)00018-8/fulltext].
  3. Уніфікований клінічний протокол первинної, вторинної (спеціалізованої), третинної (високоспеціалізованої) медичної допомоги (УКПМД) «Гіперплазія ендометрія» Available from: [https://www.dec.gov.ua/mtd/giperplaziya-endometriya/].
  4. Інструкція для медичного застосування лікарського засобу ФЕМОСТОН®.
  5. Інструкція для медичного застосування лікарського засобу ФЕМОСТОН® КОНТІ МІНІ.
  6. Інструкція для медичного застосування лікарського засобу ФЕМОСТОН® КОНТІ.

Downloads

Published

2022-08-10

How to Cite

Tatarchuk, T., Zakharenko, N., Reheda, S., & Kvasha, T. (2022). Algorithms for prescribing menopausal hormone therapy in different periods of menopause. REPRODUCTIVE ENDOCRINOLOGY, (66), 68–70. https://doi.org/10.18370/2309-4117.2022.66.68-70

Issue

No. 66 (2022)

Section

Management of menopause

License

Copyright (c) 2022 Т.Ф. Татарчук, Н.Ф. Захаренко, С.І. Регеда, Т.І. Кваша

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.